LivaNova PLC (NASDAQ:LIVN) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds.
On January 26, Brett Fishbin from KeyBanc Capital Markets revised his rating on LivaNova PLC (NASDAQ:LIVN), from Sector Weight to Overweight. The analyst estimated a target price of $81 for the stock, yielding an upside of almost 27%.
Copyright: lightwise / 123RF Stock Photo
Fishbin’s rating upgrade is part of KeyBanc’s 2026 outlook on the Medical Technology segment. The firm sees underlying trends within the segment to remain sustainable during the coming year, and also highlighted that the segment’s valuation premium has almost disappeared. This makes up for a compelling stock picking scenario that will be backed further by a higher level of capital markets activity.
Earlier, on January 9, Goldman Sachs analyst David Roman reaffirmed his Neutral rating on LivaNova PLC (NASDAQ:LIVN), while increasing the price target from $56 to $66. He anticipates more aligned valuations relative to fundamentals during 2026, after significant divergence observed during the previous year.
LivaNova PLC (NASDAQ:LIVN) is a medical technology company that develops and sells cardiovascular and neuromodulation solutions. Its cardiopulmonary segment offers heart-lung machines, oxygenators, perfusion tubing systems, cannulae, and other related accessories. The other segment, Neuromodulation, provides VNS therapy systems and devices used for neuromodulation therapies.
While we acknowledge the potential of LIVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
